Overview

• Physicians at Ruhr-University Bochum used CD19-targeted CAR T cells to specifically eliminate pathogenic B cells in two patients with treatment-resistant CIDP.
• Both patients experienced complete depletion of circulating B cells within days and regained significant motor and sensory function without further immunotherapy.
• Therapies were administered under continuous monitoring in an intermediate care unit, where moderate side effects were managed effectively with standard immune medications.
• The CAR T-cell platform was developed in partnership with Kyverna Therapeutics, integrating fully humanized chimeric antigen receptors via viral gene engineering.
• Building on these results, the Bochum team has now treated eleven patients with various severe neuroimmunological diseases, signaling broader clinical potential.